抗血管生成治疗癌症：现状与展望。

Anti-angiogenesis for cancer: Current status and prospects.

机构信息

Laboratory of Biology and Treatment of Metastasis, Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.

出版信息

Thromb Res. 2018 Apr;164 Suppl 1:S3-S6. doi: 10.1016/j.thromres.2018.01.030.

DOI:10.1016/j.thromres.2018.01.030

PMID:29703482

Abstract

Since the establishment of tumor angiogenesis as a therapeutic target, new, effective antiangiogenic agents have been developed. Despite their demonstrable clinical benefits, these therapies often have only a short-term effect, with limited impact on the overall survival of cancer patients. A question in the development of these drugs concerns their optimal use in combination regimens with newer therapeutic strategies. Here we review the current therapeutic settings combining anti-angiogenesis inhibitors with chemotherapy, PARP inhibitors or immune checkpoint blockers, focusing on ovarian cancer as tumor model.

摘要

自肿瘤血管生成被确立为治疗靶点以来，新的、有效的抗血管生成药物已经被开发出来。尽管这些治疗方法具有明显的临床益处，但它们通常只有短期效果，对癌症患者的总体生存率影响有限。这些药物开发中的一个问题是它们在与更新的治疗策略联合治疗方案中的最佳应用。本文以卵巢癌为肿瘤模型，综述了抗血管生成抑制剂与化疗、PARP 抑制剂或免疫检查点抑制剂联合治疗的现状。